ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC

Geode Capital Management LLC lifted its holdings in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 154.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 597,165 shares of the company's stock after acquiring an additional 362,221 shares during the quarter. Geode Capital Management LLC owned 1.78% of ArriVent BioPharma worth $14,036,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. FMR LLC increased its position in shares of ArriVent BioPharma by 8.7% in the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company's stock worth $49,813,000 after purchasing an additional 169,514 shares during the last quarter. Suvretta Capital Management LLC increased its holdings in ArriVent BioPharma by 7.7% in the third quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company's stock valued at $43,361,000 after buying an additional 132,459 shares during the last quarter. Novo Holdings A S raised its stake in ArriVent BioPharma by 0.4% during the third quarter. Novo Holdings A S now owns 1,505,315 shares of the company's stock valued at $35,375,000 after buying an additional 5,315 shares in the last quarter. State Street Corp lifted its holdings in ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company's stock worth $11,205,000 after buying an additional 323,186 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of ArriVent BioPharma by 153.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company's stock worth $4,756,000 after acquiring an additional 122,641 shares in the last quarter. Institutional investors and hedge funds own 9.48% of the company's stock.

ArriVent BioPharma Stock Down 1.2 %

AVBP traded down $0.31 during trading hours on Tuesday, hitting $26.64. The company's stock had a trading volume of 87,561 shares, compared to its average volume of 171,685. The company has a 50-day simple moving average of $29.10 and a 200 day simple moving average of $25.07. ArriVent BioPharma, Inc. has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Wall Street Analysts Forecast Growth

AVBP has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of ArriVent BioPharma in a report on Friday, November 15th. Citigroup boosted their price objective on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Oppenheimer restated an "outperform" rating and issued a $39.00 target price (up from $35.00) on shares of ArriVent BioPharma in a research note on Tuesday, September 10th. Finally, The Goldman Sachs Group increased their price target on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a "buy" rating in a research report on Tuesday, September 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, ArriVent BioPharma currently has a consensus rating of "Buy" and a consensus target price of $36.80.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.